Search Results

Containing any of the words

Only of the type

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease Drug Clinical Trial

Recall all batches of clearwax Drugs Circulars and withdrawal

SFDA Procedures related to Restriction of Beef Counterfeit with Horse Meat News

Safety Signal of Calcium Folinate and the Risk of Shivering Safety Alert

SFDA CEO Meets with Cambodian Minister of Commerce to Discuss Trade and Cooperation News

SFDA and KSAU Sign a Memorandum of Cooperation to Advance Training and Scientific Research News

Safety Signal of Cytarabine and the Risk of Palmar plantar erythrodysaesthesia syndrome Safety Alert

SFDA and Weqaya Sign Memorandum of Cooperation to Exchange Expertise in Shared Areas News

Safety Signal of Calcium gluconate and the Risk of Phlebitis Safety Alert

Empowering Health Care Innovation: Saudi Arabia’s Pioneering Approach to Point-of-Care Medical Device Manufacturing Scientific Magazines and articles